Lead Product(s) : Tambiciclib,Azacitidine,Venetoclax
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
SELLAS Shows Positive OS in Phase 2 SLS009 Trial for r/r AML
Details : SLS009 (GFH009) is a small molecule, highly selective CDK9 inhibitor, demostrated anti-tumor activity in the study being investigated for relapsed/refractory acute myeloid leukemia.
Product Name : SLS009
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 08, 2025
Lead Product(s) : Tambiciclib,Azacitidine,Venetoclax
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tambiciclib,Zanubrutinib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
SELLAS Reports Positive Phase 2a Data of SLS009 + Zanubrutinib in DLBCL
Details : SLS009 (GFH009) is a small molecule, highly selective CDK9 inhibitor, demostrated anti-tumor activity. It is being investigated for the treatment of relapsed/refractory diffuse large B-cell lymphoma.
Product Name : SLS009
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 20, 2025
Lead Product(s) : Tambiciclib,Zanubrutinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable